Regeneron Pharmaceuticals. (REGN), Sanofi Win Approval of Zaltrap for Colon Cancer - Bloomberg
Tweet Send to a Friend
Up)
Regeneron Pharmaceuticals. (Nasdaq: REGN), Sanofi Win Approval of Zaltrap for Colon Cancer - Bloomberg
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Sanofi (SNY), Regeneron (REGN) Report Publication of Positive Dupilumab Phase 2a Data
- VIVUS, Inc. (VVUS) to Make Several Scientific Presentations in May
- Hologic (HOLX) Announces FDA Approval of C-View 2D Imaging for or Breast Cancer Screening
Create E-mail Alert Related Categories
FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
